← Back to all trials
Completed
NCT06477484
Blood Biomarkers for Screening of Alzheimer's Disease
Conditions: Alzheimer's Disease, Blood Biomarkers
Sex: All
Ages: 50 Years – N/A
Healthy volunteers: Yes
Enrollment: 180
Sponsor: Peking University First Hospital
Location: Peking University First Hospital Beijing Beijing Municipality
Summary
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:
* to identify core blood biomarker suitable for early screening of AD.
* to establish a comprehensive model for the early identification of AD.
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 50 years;
* AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
* Signed informed consent form.
Exclusion Criteria:
* The presence of other disorders that can cause cognitive impairment;
* Unable to cooperate with the completion of cognitive assessment;
* Refusal to draw blood.
Source: ClinicalTrials.gov (NCT06477484). StuddyBuddy aggregates publicly available trial information.
